Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548971
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-03
Brief Title:
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke TREND-IVT
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Safety and Efficacy of Treatment With Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke TREND-IVT A Multicenter Randomized Placebo-controlled Clinical Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TREND-IVT
Brief Summary:
Stroke is the second leading cause of death worldwide and ischemic stroke is the most frequent type Intravenous thrombolysis with recombinant tissue plasminogen activator within 45 hours of symptom onset is the most effective therapy for patients with acute ischemic stroke However ischemic stroke progression and early reocclusion are not an uncommon phenomenon in patients after intravenous thrombolysis resulting in neurological deterioration which is associated with unfavorable functional outcomes The underlying mechanism mainly involves the augmented platelet activation triggered by the activated coagulation cascade during thrombolysis which peaks within 2 hours of initiating rt-PA administration Therefore early antiplatelet therapy following intravenous thrombolysis represents a promising therapeutic approach to prevent neurological deterioration and improve the functional outcome of patients treated with intravenous thrombolysis
Currently guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear
The study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage
Currently guidelines recommend initiating antiplatelet therapy 24 hours after intravenous thrombolysis due to the potential risk of increased bleeding The safety and efficacy of early antiplatelet treatment following intravenous thrombolysis in patients with acute ischemic stroke remain clear
The study aims to test the hypothesis that in patients with acute ischemic stroke treated with intravenous thrombolysis early administration of oral aspirin will improve functional outcomes without increasing the risk of intracranial hemorrhage
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None